Our offerings under Regulation D Rule 506(c) are available to accredited investors only.
GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV

Dr. David Karli – Future of Biotechnology

In this Show

Exosomes are tiny structures released by a cell to communicate with other cells and stimulate a response in the target cell. Scientists continue to learn not only how these tiny structures function, but more importantly, how they can be developed into bio therapies in the future. Check out this cool post on how science, medicine and industry will develop exosomes as a next generation of bio therapies.

Get in contact with David C. Karli through his website, LinkedIn and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/

(Visited 5 times, 1 visits today)